Catalyst Event
Akeso Inc (9926) · Earnings Release
From Akros SCHK HK-US Biotech Index (ASHUBIO)
3/26/2026, 12:00:00 AM
Akeso announced its full-year 2025 financial results on March 26, 2026. Revenue grew 43.9% year-over-year to RMB 3.06 billion, but the net loss widened to RMB 1.11 billion, missing analyst expectations. High importance estimated due to potential for >10% price impact from significant earnings miss, expected.
Korean Translation
2026년 3월 26일 2025년 연간 실적 발표. 매출은 전년 대비 43.9% 증가한 30억 6천만 위안을 기록했으나, 순손실은 11억 1천만 위안으로 확대되어 분석가 예상치를 하회함. 실적 하회에 따른 10% 이상의 주가 영향이 예상되어 High 등급으로 분류함. 예상됨.
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
High importance is estimated due to the potential for significant price volatility for Pfizer's Q1 2026 earnings release and conference call, scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release and conference call scheduled; typically results in moderate price movement.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release and conference call scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Q1 2026 earnings release and conference call for 2026-04-30, estimated to have a low impact of ~1-2% based on historical trends, scheduled.
4/30/2026, 12:00:00 AM
Regeneron Pharmaceuticals Inc (REGN) · Earnings Release
Regeneron is scheduled to report its first quarter 2026 financial and operating results on 2026-04-29. Importance is Medium as earnings typically drive significant price movement, scheduled.
4/29/2026, 12:00:00 AM